Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2021-01-13
Target enrollment:
Participant gender:
Summary
Study D9108C00002 (NeoCOAST) is a platform study assessing the effectiveness and safety of
neoadjuvant durvalumab alone or in combination with novel agents in subjects with resectable,
early-stage (Stage I [>2cm] to IIIA) non-small cell lung cancer (NSCLC).